This episode of The Motley Fool's Market Checkup is dedicated to the world's largest pure-play biotech stock, Gilead Sciences (GILD 2.13%). Market Checkup gives a full examination of Gilead's second-quarter results, takes a closer look at the company's current product portfolio, and analyzes the future drugs that have investors excited about the stock's future.
In this video, health-care analysts David Williamson and Max Macaluso drill down on Gilead's strong second-quarter results. Watch and find out why Gilead's performed so well lately, and which drugs drove quarterly results higher.
Follow David on Twitter: @MotleyDavid.
